Standout Papers

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remittin... 2012 2026 2016 2021 868
  1. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012)
    Jeffrey Cohen, Alasdair Coles et al. The Lancet
  2. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (2012)
    Alasdair Coles, Cary Twyman et al. The Lancet
  3. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial (2020)
    Anthony Traboulsee, Benjamin Greenberg et al. The Lancet Neurology

Immediate Impact

10 from Science/Nature 55 standout
Sub-graph 1 of 22

Citing Papers

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
2025 Standout
Past, present, and future of CRISPR genome editing technologies
2024 Standout
2 intermediate papers

Works of Edward Fox being referenced

Alemtuzumab CARE-MS I 5-year follow-up
2017
Accuracy of Next Generation Sequencing Platforms.
2014
and 3 more

Author Peers

Author Last Decade Papers Cites
Edward Fox 3509 1309 722 1498 1485 154 5.8k
Janine Wechsler 2855 1349 425 705 2206 190 7.5k
Nicolás Ortonne 1334 880 585 725 685 199 4.6k
Riccardo Saccardi 2213 601 675 486 1453 179 6.0k
Michael Møller 1573 655 287 538 1263 154 4.1k
John Lister 1972 410 772 379 1547 177 7.1k
Thomas F.E. Barth 2365 447 887 403 2005 233 6.8k
Óscar Fernández 2863 924 132 1131 917 194 4.6k
Peter Chang 1327 715 999 510 758 148 4.3k
Thierry Jo Molina 3491 256 503 1123 3298 251 9.0k
G. Richard Dickersin 1364 1699 1727 614 1877 120 7.3k

All Works

Loading papers...

Rankless by CCL
2026